A Dose-ranging Pediatric Study of an Adjuvanted Pandemic Influenza Vaccine

A Phase 2, Randomized, Observer-Blind, Multicenter Study to Evaluate the Immunogenicity and Safety of Several Doses of Antigen and MF59 Adjuvant Content in a Monovalent H5N1 Pandemic Influenza Vaccine in Healthy Pediatric Subjects 6 Months to < 9 Years of Age

The purpose/aim of this study is to evaluate responses to vaccination with different MF59 adjuvanted pandemic influenza vaccine formulations of an H5N1 vaccine in pediatric subjects. The data from this study are intended to provide information for health authorities to determine the best formulation for protection of children during the pandemic phase of a pandemic of a novel pandemic influenza strain (World Health Organization (WHO) 2013).

A Dose-ranging Pediatric Study of an Adjuvanted Pandemic Influenza Vaccine

Recruitment

Summary

Participation Requirements

Description

Tracking Information